Skip to main content
. 2022 May 15;14(5):1002–1013. doi: 10.4251/wjgo.v14.i5.1002

Table 3.

Univariate and multivariate analyses of prognostic factors for progression-free survival for all patients

Variables Univariate analyses

Multivariate analyses


HR (95%CI)
P value
HR (95%CI)
P value
Gender (male vs female) 0.759 (0.554-1.041) 0.087 0.772 (0.529-1.126) 0.179
Age (> 60 vs ≤ 60) 1.162 (0.830-1.626) 0.382 0.955 (0.654-1.395) 0.813
Smoking status (Yes vs No) 0.805 (0.550-1.177) 0.262 1.227 (0.781-1.927) 0.375
Number of involved sites (multiple vs one) 1.484 (1.083-2.034) 0.014 1.223 (0.880-1.701) 0.231
Liver metastasis (Yes vs No) 0.950 (0.674-1.339) 0.770 0.737 (0.506-1.073) 0.112
Bone metastasis (Yes vs No) 1.219 (0.762-1.951) 0.409 1.232 (0.754-2.011) 0.405
Treatment regimens (combination chemotherapy vs others) 0.448 (0.313-0.639) 0.000 0.398 (0.263-0.594) 0.000
AAPR (> 0.48 vs ≤ 0.48) 0.611 (0.446-0.837) 0.002 0.527 (0.370-0.751) 0.000

HR: Hazard ratio; CI: Confidence interval; AAPR: Albumin-to-alkaline phosphatase ratio.